7月16日，美敦力盘中上涨3.2%，报83.795美元/股，成交额7412.43万美元。
消息面上，美敦力宣布已完成对SPR Therapeutics的收购，预付现金对价6.5亿美元。SPR专注于微创、非阿片类慢性与急性疼痛治疗方案，此次交易将进一步强化美敦力在疼痛管理领域的布局。公司预计该收购对2027财年调整后每股收益的稀释影响较小，此后将转为中性至增厚。
此外，板块整体表现强劲，雅培涨12.32%，史赛克涨5.19%，波士顿科学涨4.79%。近期多家机构上调美敦力目标价，贝尔德上调至91美元，BTIG维持买入评级并将目标价调至91美元，分析师平均目标价96.12美元，较当前股价仍有上行空间。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.